1646

OLD B MILE

PTO/SB/17 (10-02)
Approved for use through 10/31/2002. OMB 0651-0032
Index to Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

METHOD OF PAYMENT (check	all that apply)	FEE CALC	ULATION (continu	ied)	
TOTAL AMOUNT OF PAYMENT	(\$) 0.00	Attorney Docket No.	PF199D2	TECH CENTER	<u> </u> 600/2900
Applicant claims small entity statu	s. See 37 CFR 1.27	Group Art Unit	1646		
		Examiner Name	P. Mertz	DEC 2 O	2002
Patent fees are subject to an		First Named Inventor	Jian Ni	HLULI	VLD
for FY 20	ነበ3	Filing Date	July 24, 2001	RECEI	
FEE TRANSMITTAL		Application Number	09/911,346-0		
		Co	٠.		
Under ME Paperwork Reduction Act of 19		red to respond to a collection of information	ation unless it displays	s a valid OMB control number.	<u>.</u> `

TOTAL AMOUNT OF PAYMENT (\$) 0.00	Attorney Docket No. PF199D2 TECH CENTER					FNIFK	
METHOD OF PAYMENT (check all that apply)				FEE	CALCUL	_ATION (continued)	
Check Credit Money Order Other None	3. ADDITIONAL FEES						
x Deposit Account	١						
Deposit Account 08-3425	Fee	Large Entity Small Entity Fee					
Account 08-3425 Number		(\$)	Code	(\$)	Fee Description		Fee Paid
Deposit Account Human Genome Sciences, Inc.	1051	130	2051	65	Surcharge	- late filing fee or oath	
Name	1052	50	2052	25	Surcharge		
The Commissioner is hereby authorized to: (check all that apply)					sheet.		
Charge fee(s) indicated below X Credit any overpayments	1053	130	1053	130	Non-Englis	h specification	
X Charge any additional fee(s) during the pendency of this application	1812	2,520	1812	2,520	•	equest for ex parte reexamination	
Charge fee(s) indicated below, except for the filing fee	1804	920*	1804	920*	Requesting Examiner a	publication of SIR prior to action	
to the above-identified deposit account.	1805	1,840*	1805	1,840*	Requesting Examiner a	publication of SIR after	
FEE CALCULATION	1251	110	2251	55	Extension f	for reply within first month	
1. BASIC FILING FEE	1252	400	2252	200	Extension f	for reply within second month	
Large Entity Small Entity	1253	920	2253	460	Extension f	for reply within third month	
Fee Fee Fee Fee Fee Description Fee Paid	1254	1,440	2254	720	Extension f	for reply within fourth month	
1001 740 2001 370 Utility filing fee	1255	1,960	2255	980	Extension f	for reply within fifth month	
1002 330 2002 165 Design filing fee	1401	320	2401	160	Notice of A	ppeal	
1003 510 2003 255 Plant filing fee	1402	320	2402	160	Filing a brie	ef in support of an appeal	
1004 740 2004 370 Reissue filing fee	1403	280	2403	140	Request for	r oral hearing	
1005 160 2005 80 Provisional filing fee	1451	1,510	1451	1,510	Petition to i	institute a public use proceeding	
SUBTOTAL (1) (\$) 0.00	1452	110	2452	55	Petition to r	revive – unavoidable	
	1453	1,280	2453	640	Petition to r	revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,280	2501	640	Utility issue	e fee (or reissue)	
Extra Fee from Claims below Fee Paid	1502	460	2502	230	Design issu	ue fee	:
Total Claims -20** = x =	1503	620	2503	310	Plant issue	fee	
Independent -3** = x = x	1460	130	1460	130	Petitions to	the Commissioner	
Multiple Dependent =	1807	50	1807	50	Processing	fee under 37 CFR 1.17(q)	
Large Entity Small Entity	1806	180	1806	180	Submission	of Information Disclosure Stmt	
Fee Fee Fee Code (\$) Fee Description	8021	40	8021	40		each patent assignment per mes number of properties)	
1202 18 2202 9 Claims in excess of 20	1809	740	2809	370	Filing a sub (37 CFR 1.	omission after final rejection 129(a))	
1201 84 2201 42 Independent claims in excess of 3  1203 280 2203 140 Multiple dependent claim, if not paid	1810	740	2810	370	For each a	dditional invention to be 37CFR 1.129(b))	
1204 84 2204 42 ** Reissue independent claims	1801	740	2801	370		r Continued Examination (RCE)	
over original patent	1802	900	1802	900	Request for	r expedited examination	
1205 18 2205 9 Reissue claims in excess of 20   of a det				of a design	application ·	<del></del>	
	Other fee (specify)					<u> </u>	
SUBTOTAL (2) (\$) 0.00	*Redu	iced by E	Basic Fi	ling Fee	Paid	SUBTOTAL (3) (\$)	0.00
**or number previously paid, if greater, For Reissues, see above	<u> </u>						

SUBMITTED BY					Complete (if applicable)		
Name (Print/Type)	Lin J. Hymel	·	Registration No. (Attorney/Agent)	45,414	Telephone	(301) 251-6015	
Signature	1 1	. Hy			Date	December 18, 2002	
		, ,,					

ECH CENTER 1600/2900

## UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Docket No.: PF199D2

Ni et al.

Application No.: 09/911,346

Group Art Unit: 1646

Filed: July 24, 2001

Examiner: P. Mertz

For: Natural Killer Cell Enhancing Factor C

## PROVISIONAL ELECTION UNDER 37 C.F.R. § 1.143 WITH TRAVERSE

Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the Office Action dated November 18, 2002, please consider the following provisional election with traverse. Applicants submit concurrently herewith: (a) a Fee Transmittal Sheet; (b) Marked-Up Copy of the Specification.

## **Provisional Election With Traverse**

The Examiner has separated the pending claims into three different groups and has required an election under 35 U.S.C. § 121. See, Paper No. 6, page 2-3.

In order to be fully responsive, Applicants hereby provisionally elect, with traverse, the claims currently restricted to Group I (i.e., claims 1-20, 29-52, 61-83, 92-115, and 124-127 drawn to antibodies).

With respect to separation of the claimed invention into three (3) groups and the reasons stated therefore, Applicants respectfully traverse. It was asserted in the restriction requirement that Groups I, II, and III claims represent distinct inventions because "the antibody of invention I as claimed can be used in the process of immunochromatography, to purify the NKEF C protein." See, Paper No. 6, page 2. It was then concluded:

> Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classifications and recognized divergent subject matter as

defined by MPEP.. § 808.02, the Examiner has *prima facie* shown a serious burden of search (see MPEP..§ 803)."

Id. at 2-3.

Applicants respectfully submit, however, that it would not entail a serious burden to examine all pending claims together, because a search of the antibody claims can be expected to provide all necessary information for the method of detecting and method of treatment claims. In particular, any publication that describes use of the claimed antibody in a method of detection or treatment must necessarily describe the antibody that is used therein. Therefore, any publications that might potentially disclose the presently claimed antibody would also encompass all publications disclosing methods of using that antibody (whether it be for detection or treatment purposes).

Accordingly, Applicants respectfully request that the restriction requirement under 35 U.S.C § 121 be reconsidered and withdrawn and the instant claims be examined in one application.

## Request for Rejoinder of Product and Method of use Claims:

Furthermore, if the restriction requirement is maintained, Applicants request rejoinder of the claims of Groups I, II and III once the claims of Group I are found allowable. In light of the decisions in *In re Ochiai*, 71 F.3d 1565, 37 USPQ2d 1127 (Fed. Cir. 1995) and *In re Brouwer*, 77 F.3d 422, 37 USPQ 2d 1663 (Fed. Cir. 1996), a notice was published in the Official Gazette which set forth new guidelines for the treatment of product and process claims. *See* 1184 OG 86 (March 26, 1996). Specifically, the notice states that:

in the case of an elected product claim, rejoinder will be permitted when a product claim is found allowable and the withdrawn process claim depends from or otherwise includes all the limitations of an allowed product claim.

Id. Accordingly, if claims of Group I are found allowable, Applicants respectfully request that the claims of Groups II and III be rejoined and examined for patentability. See also M.P.E.P. § 821.04. Applicants retain the right to petition from the restriction requirement under 37 C.F.R. § 1.144.